OssiMend Bioactive Moldable in Posterolateral Instrumented Lumbar Fusion

Status: Recruiting
Location: See all (4) locations...
Intervention Type: Device
Study Type: Observational
SUMMARY

The primary objective of this study is to measure the success rate of lumbar fusion in subjects at 12 months when instrumented lumbar arthrodesis is performed using OssiMend Bioactive Moldable as the bone grafting material

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Subject must be 18 years of age or older at the time of consent and must have a documented diagnosis of degenerative disc disease (DDD) that has failed to respond to nonoperative treatment for at least 6 months. DDD is defined by back and/or radicular pain with degeneration of the disc as confirmed by medical history, physical examination, and radiographic studies that may include CT, MRI, plain X-ray film, discography, myelography, etc. with one or more of the following findings:

‣ Instability as defined by \>3mm translation or \>5 degrees angulation

⁃ Osteophyte formation of facet joints or vertebral endplates

⁃ Decreased disc height, on average by \>2mm, but dependent upon the spinal level

⁃ Herniated nucleus pulposus

⁃ Facet joint degeneration/changes

Locations
United States
California
San Diego Neurosurgery
NOT_YET_RECRUITING
Encinitas
Connecticut
Hartford Hospital
RECRUITING
Hartford
New Jersey
University Orthopaedic Associates, Division of OrthoNJ
NOT_YET_RECRUITING
Somerset
Oregon
McKenzie-willamette Medical Center
COMPLETED
Eugene
Contact Information
Primary
Meenakshi Paliwal
mpaliwal@collagenmatrix.com
12014051477
Backup
Peggy Hansen
phansen@collagenmatrix.com
201-405-1477
Time Frame
Start Date: 2021-01-21
Estimated Completion Date: 2027-01-30
Participants
Target number of participants: 120
Treatments
OssiMend™ Bioactive Moldable
Patients undergoing Lumber Spine Fusion
Related Therapeutic Areas
Sponsors
Leads: Collagen Matrix

This content was sourced from clinicaltrials.gov

Similar Clinical Trials